打开APP

GEN:2014生物制药企业研发投入25强

  1. GEN
  2. 投资
  3. 排名
  4. 生物制药
  5. 研发

来源:生物谷 2015-03-04 12:17

现如今,大型药企或许已经在削减其R&D部门,然而生物技术巨头们仍在加强研发投入。GEN汇总了今年生物医药企业研发投入前25强发现共投入1004.41亿美元,其中前20强共投入941.08亿美元。

GEN:2014生物制药企业研发投入25强

2015年3月3日讯/生物谷BIOON/--现如今,大型药企或许已经在削减其R&D部门,然而生物技术巨头们仍在加强研发投入。GEN汇总了今年生物医药企业研发投入前25强发现共投入1004.41亿美元,其中前20强共投入941.08亿美元。

实际上,制药巨头们在研发上的投入也并不比四年前少多少。2014年,前10大制药巨头的研发投入共690.77亿美元,仅仅比2011年的694.59亿美元减少了1%。而6家同时存在于2011年和2014年两份榜单中的6家生物技术公司,其研发投入比三年前增加了50%,共增加了148.5亿美元。相较而言,生物公司在研发投入上的增幅要超过大型的制药企业。

生物技术公司加强研发投入的原因各异,其中重要的原因在于近期是许多产品投放市场前试验的最后阶段,最为成功的例子就是吉利德的Sovaldi,该药物跻身GEN排名的2014年销售量25强榜单第二。

与此同时,过去的一段时间是大大小小药企之间的并购热潮期,收购其他公司的大企业也会继续开展对被收购方已有项目的研发。除此之外还有一些原因,比方说合作双方会以研发预付款的方式展开合作,承诺为合作对象的研发投资。榜单上的一家公司就已经同意支付10亿美元的研发预付款。

下表就是GEN排名的2014年研发投入前25强榜单,数据包括每家公司2014年和2013年的研发投入,以及前者相较后者的变化百分比。

GEN:2014生物制药企业研发投入25强

由于德国默克集团没有发布2014年全年的研发数据,因此榜单暂不列出。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!转载请注明来源并附原文链接。更多资讯请下载生物谷APP

原文 Top 25 Biopharma R&D Spenders of 2014

Big pharma may be retreating from internal R&D, but big biotech has more than made up for it with its own ramped-up research spending. This year’s Top 25 Biopharma R&D Spenders plunked down $100.441 billion on research, including $94.108 billion from the top 20; up 6% from the $88.643 billion spent in 2011 by the Top 20 on GEN’s first such list.

How much less is big pharma spending? Not too much less than four years ago, actually. The 10 largest heritage drug developers on the List shelled out a combined $69.077 billion in 2014, less than 1% below the $69.459 billion spent in 2011. The six biotechs appearing in both years’ Lists spent nearly 50% more on R&D in 2014 than three years earlier, their combined total jumping since 2011 to $14.85 billion. Their increases in R&D are larger than those of big pharmas—though it should be noted that only four companies on this List spent less on R&D in 2014 than 2013, though two companies have alerted investors they plan to cut back in 2015.

Reasons for the big biotech R&D surge are almost as varied as the companies involved. Biotech giants have spent recent years finalizing numerous late-stage trials for products that only lately have been launched to market. The most successful of those big-biotech drugs is Gilead Sciences’ Sovaldi, which zoomed to #2 on last week’s GEN List of Top 25 Best-Selling Drugs of 2014, cracking the eight-figure sales benchmark.

Also, drug developers big and small have been gobbling each other up through mergers and acquisitions, many of which involved buyers that continued the R&D programs of the companies they bought. Another less obvious reason: The collaborations that are taking the place of internal R&D often involve upfront payments and promises to pay for a partner’s research, both funded through R&D budgets. One company on this List agreed to spend more than $1 billion upfront.

Following is this year’s list of 25 biopharmas, ranked by their GAAP spending on R&D in 2014, as reported in annual filings or press releases. Each company is listed by name, 2014 R&D spending, 2013 R&D spending, and the percentage change from 2013.

This year’s List omits one company that has appeared in past years’ lists of Top R&D Spenders. Merck KGaA was not scheduled to release full-year 2014 results until after the deadline of this List (March 3).

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->